论文部分内容阅读
目前我国SFDA已批准应用于治疗慢性乙型病毒性肝炎(慢乙肝)的抗病毒药物分为2类6种:干扰素(α-干扰素、聚乙二醇α-干扰素)和核苷(酸)类似物(拉米夫定、阿德福韦、恩替卡韦、替比夫定),在欧美国家进入临床的核苷酸类药物还有替诺福韦,恩曲他滨和克来夫定也在临床试验中。本文就核苷(酸)类药物在慢乙肝抗病毒治疗的机制、疗效、及耐药进行扼要阐述。
At present, our country SFDA has been approved for the treatment of chronic hepatitis B (chronic hepatitis B) antiviral drugs divided into two types of 6: interferon (α-interferon, polyethylene glycol α-interferon) and nucleosides ( Acid) analogs (lamivudine, adefovir, entecavir, telbivudine), in the United States and Europe into the clinical nucleotide class also tenofovir, emtricitabine and clevudine Also in clinical trials. In this paper, nucleoside (acid) drugs in chronic hepatitis B antiviral therapy mechanism, efficacy, and resistance are briefly described.